Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus

INTRODUCTION: Immune checkpoint inhibitors (ICI) produce dramatic tumor shrinkage and durable responses in many advanced malignancies, but their use is limited by the development of immune-related adverse events (IRAEs) that occur in up to 60% of patients and often affect endocrine organs. Concern f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilder, Robin, Tsai, Karen, Quandt, Zoe, Isaacs, Dayna, Drakaki, Alexandra, Xing, Yan, In, Gino K., Angell, Trevor E., Lechner, Melissa G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643762/
https://www.ncbi.nlm.nih.gov/pubmed/38027216
http://dx.doi.org/10.3389/fendo.2023.1242830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643762/
https://www.ncbi.nlm.nih.gov/pubmed/38027216
http://dx.doi.org/10.3389/fendo.2023.1242830

Ejemplares similares